论文部分内容阅读
目的 :用司帕沙星与洛美沙星随机对照治疗急性呼吸系统细菌性感染 ,对前者进行安全性及有效性评价。方法 :剂量为司帕沙星 2 0 0mg ,QD ,疗程 5～ 14天 ,洛美沙星 2 0 0mgBid ,餐后 1小时服用 ,疗程 5～ 14天。结果 :共完成 82例 (试验组 42例 ,其中 1例只计不良反应 ,对照组 40例 ) ,病种包括化脓性扁桃腺炎、扁桃腺周围脓肿、急慢性支气管炎、肺炎、支气管扩张症伴感染等 ,试验组与对照组对不同感染病种患者的有效率分别为 87 80 %与 73 12 % ,试验组、对照组不同细菌感染者的有效率为 87 18%与 73 6 8% ,组间无显著性差异 (P >0 0 5 ) ,两组细菌清除率分别为 92 31%与 81 5 8% ,不良反应发生率分别为 9 5 2 %与 5 0 0 % ,差异无显著性 (P >0 0 5 )。 77株细菌对司帕沙星与洛美沙星高敏率为 81 12 %与 6 7 5 3%。结论 :司帕沙星抗菌谱广 ,抗菌活性强 ,为一治疗轻、中度急性呼吸系统细菌性感染安全有效的口服药物。
OBJECTIVE: To evaluate the safety and efficacy of sparfloxacin and lomefloxacin in the treatment of acute bacterial infections of the respiratory system. Methods: The dose of sparfloxacin 200mg, QD, treatment of 5 to 14 days, lomefloxacin 200mgBid, 1 hour after taking the meal, treatment of 5 to 14 days. Results: A total of 82 cases were completed (42 cases in trial group, of which 1 case was adverse reaction and 40 cases in control group). The disease types included purulent tonsillitis, peritonsillar abscess, acute and chronic bronchitis, pneumonia, bronchiectasis With infection, the test group and control group for different infectious diseases were 87 80% and 73 12% effective rate of the experimental group, the control group of different bacterial infections were 87 18% and 73 6 8%, respectively, There was no significant difference between the two groups (P> 0.05). The bacterial clearance rates of the two groups were 92.31% and 81.58% respectively, and the rates of adverse reactions were 95.2% and 500.0% respectively, with no significant difference (P> 0 0 5). 77 strains of sparfloxacin and lomefloxacin high sensitivity 81 12% and 6 7 5 3%. Conclusion: Sparfloxacin antibacterial spectrum is wide, strong antibacterial activity, for the treatment of mild to moderate bacterial infections of acute respiratory infections safe and effective.